(Q43556611)

24 November 2017

title

The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma (English)

1 reference

24 November 2017

1 reference

22

Vernon K Sondak

1 reference

24 November 2017

10

Thomas Gajewski

1 reference

24 November 2017

18

Donald Morton

1 reference

24 November 2017

3

F Stephen Hodi

1 reference

24 November 2017

14

Michael Lotze

1 reference

24 November 2017

Howard L Kaufman

1

1 reference

24 November 2017

John M Kirkwood

2

1 reference

24 November 2017

Sanjiv Agarwala

4

1 reference

24 November 2017

Thomas Amatruda

5

1 reference

24 November 2017

Steven D Bines

6

1 reference

24 November 2017

Joseph I Clark

7

1 reference

24 November 2017

Brendan Curti

8

1 reference

24 November 2017

Marc S Ernstoff

9

1 reference

24 November 2017

Rene Gonzalez

11

1 reference

24 November 2017

Laura Jane Hyde

12

1 reference

24 November 2017

David Lawson

13

1 reference

24 November 2017

Jose Lutzky

15

1 reference

24 November 2017

Kim Margolin

16

1 reference

24 November 2017

David F McDermott

17

1 reference

24 November 2017

Anna Pavlick

19

1 reference

24 November 2017

Jon M Richards

20

1 reference

24 November 2017

William Sharfman

21

1 reference

24 November 2017

Jeffrey Sosman

23

1 reference

24 November 2017

Susan Steel

24

1 reference

24 November 2017

Ahmad Tarhini

25

1 reference

24 November 2017

John A Thompson

26

1 reference

24 November 2017

Jill Titze

27

1 reference

24 November 2017

Walter Urba

28

1 reference

24 November 2017

Richard White

29

1 reference

24 November 2017

Michael B Atkins

30

1 reference

24 November 2017

language of work or name

English

0 references

publication date

27 August 2013

1 reference

Nature Reviews Clinical Oncology

24 November 2017

published in

1 reference

24 November 2017

volume

10

1 reference

24 November 2017

issue

10

1 reference

24 November 2017

page(s)

588-598

1 reference

Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported

24 November 2017

copyright license

start time

27 August 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Systematic review of medical treatment in melanoma: current status and future prospects.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Final version of 2009 AJCC melanoma staging and classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Management of immune-related adverse events and kinetics of response with ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Improved endpoints for cancer immunotherapy trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Predicting survival outcome of localized melanoma: an electronic prediction tool based on the AJCC Melanoma Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

IFN-α in the treatment of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of C

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Interferon alpha as adjuvant postsurgical treatment of melanoma: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Survival after pulmonary metastasectomy in patients with malignant melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Does metastasectomy improve survival in patients with Stage IV melanoma? A cancer registry analysis of outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Patient responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: how different are these from conventional treatment responses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Ipilimumab in the treatment of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Long-term interferon-alpha therapy induces autoantibodies against epidermis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Induction of myasthenia gravis, myositis, and insulin-dependent diabetes mellitus by high-dose interleukin-2 in a patient with renal cell cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Prognostic significance of autoimmunity during treatment of melanoma with interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Guidelines for the safe administration of high-dose interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Serum amino acids, biopterin and neopterin during long-term immunotherapy with interferon-alpha in high-risk melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Paroxetine for the prevention of depression induced by high-dose interferon alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Level of scientific evidence underlying recommendations arising from the National Comprehensive Cancer Network clinical practice guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Immunologic correlates of the abscopal effect in a patient with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Regimens with or without interferon-alpha as treatment for metastatic melanoma and renal cell carcinoma: an overview of randomized trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Surgical management of melanoma lung metastasis: an analysis of survival outcomes in 292 consecutive patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Feasibility of intensity-modulated radiation therapy in the treatment of advanced cervical chordoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Suppressed thyroid-stimulating hormone secretion in patients treated with interleukin-2 and interferon-alpha 2b for metastatic melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Phase II study of intermittent continuous infusion of low-dose recombinant interleukin-2 in advanced melanoma and renal cell cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Low-dose IL-2 treatment: Activation of discrete T- and NK-cell sub-populationsin vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Autoimmunity and immunotherapy for cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Interferon-alpha influences tryptophan metabolism without inducing psychiatric side effects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

Low-dose recombinant IL-2 induces psychological changes: monitoring by Minnesota Multiphasic Personality Inventory (MMPI).

31 March 2020

1 reference

12 December 2020

Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2

1 reference

12 December 2020

Randomized trial of recombinant alpha 2b-interferon with or without indomethacin in patients with metastatic malignant melanoma.

1 reference

12 December 2020

[Adjuvant adoptive immunotherapy in patients with stage III and resected stage IV melanoma: a pilot study]

1 reference

12 December 2020

Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy

1 reference

12 December 2020

Phase I trial of interleukin 2 in combination with the soluble tumor necrosis factor receptor p75 IgG chimera

1 reference

12 December 2020

Toxicity of adjuvant high-dose interferon-alpha-2b in patients with cutaneous melanoma at high risk of recurrence.

1 reference

12 December 2020

Dose-dependent development of depressive symptoms during adjuvant interferon-{alpha} treatment of patients with malignant melanoma.

1 reference

12 December 2020

High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update

1 reference

12 December 2020

The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases

1 reference

12 December 2020

A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor

1 reference

12 December 2020

Treatment of metastatic malignant melanoma with interleukin-2

1 reference

12 December 2020

Clinical Practice Guidelines We Can Trust

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.153

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/NRCLINONC.2013.153

1 reference

release_ow3ucednt5dwliei2yy4ykjvra

24 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ow3ucednt5dwliei2yy4ykjvra

24 November 2022

mapped directly with Wikidata item

1 reference